caa a22 4500 605490767 CHVBK 20210128100506.0 cr unu---uuuuu 210128e20151201xx s 000 0 eng 10.1007/s10147-015-0828-1 doi (NATIONALLICENCE)springer-10.1007/s10147-015-0828-1 Surveillance policy for Japanese patients with stage I testicular germ cell cancer in the multi-detector computed tomography era [Elektronische Daten] [Takeshi Yuasa, Naoko Inoshita, Hajime Tanaka, Shinji Urakami, Shinya Yamamoto, Yasuhisa Fujii, Hitoshi Masuda, Iwao Fukui, Yuichi Ishikawa, Junji Yonese] Background: The outcome of surveillance for Japanese patients with clinical stage I testicular germ cell cancer (GCC) was investigated in the multi-detector computed tomography (MDCT) era. Methods: The medical records of 92 Japanese patients with stage I GCC, who received treatment in our institution between March 1999 and February 2013, were reviewed. As six patients requested and received prophylactic chemotherapy and two patients seriously deviated from surveillance schedule, these patients were excluded from the study. Data from a total 84 patients were analyzed, Results: The median follow-up period following diagnosis was 5.1years (inter-quartile range: IQR, 2.3-7.7years). Of the 84 patients, eight (9.5%) had a recurrence of their cancer in this observation period. Regarding histologic subtypes, the recurrence rates were five (9.3%) of the 54 patients with seminoma and three (10%) of the 30 patients with nonseminomatous germ cell tumor (NSGCT). All eight patients who experienced a recurrence did so within 2years; they all underwent induction chemotherapy and remain alive at the time of writing, with no evidence of disease. Among 31 seminoma patients with a tumor more than 4cm in size and rete testis invasion, cancer recurred in three (9.7%) during the surveillance period. On the other hand, among the 13 patients with NSGCT and vascular invasion, three (23%) experienced a recurrence, whereas the figure was zero for the 11 (0%) patients without vascular invasion. Conclusion: Fewer than 10% of Japanese patients with stage I testicular GCC suffered a recurrence in the 5-year observation period of this study. The risk of occult disease, which will result in relapse, might be decreased in the MDCT era. All patients must be fully informed of the anticipated recurrence rate and the potential risks of exposure to chemotherapy agents. Japan Society of Clinical Oncology, 2015 Testicular cancer nationallicence Germ cell cancer nationallicence Stage I nationallicence Surveillance nationallicence Multi-detector computed tomography nationallicence Recurrence free survival nationallicence GCC : Germ cell cancer nationallicence NSGCT : Nonseminomatous germ cell tumor nationallicence MDCT : Multi-detector computed tomography nationallicence CT : Computed tomography nationallicence AFP : Alpha-fetoprotein nationallicence hCG : Human chorionic gonadotropin nationallicence LDH : Lactate dehydrogenase nationallicence BEP : Bleomycin, etoposide, and cisplatin nationallicence Yuasa Takeshi Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan aut Inoshita Naoko Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan aut Tanaka Hajime Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan aut Urakami Shinji Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan aut Yamamoto Shinya Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan aut Fujii Yasuhisa Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan aut Masuda Hitoshi Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan aut Fukui Iwao Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan aut Ishikawa Yuichi Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan aut Yonese Junji Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan aut International Journal of Clinical Oncology Springer Japan 20/6(2015-12-01), 1198-1202 1341-9625 20:6<1198 2015 20 10147 https://doi.org/10.1007/s10147-015-0828-1 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-015-0828-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Yuasa Takeshi Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan aut NATIONALLICENCE 700 1- Inoshita Naoko Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan aut NATIONALLICENCE 700 1- Tanaka Hajime Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan aut NATIONALLICENCE 700 1- Urakami Shinji Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan aut NATIONALLICENCE 700 1- Yamamoto Shinya Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan aut NATIONALLICENCE 700 1- Fujii Yasuhisa Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan aut NATIONALLICENCE 700 1- Masuda Hitoshi Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan aut NATIONALLICENCE 700 1- Fukui Iwao Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan aut NATIONALLICENCE 700 1- Ishikawa Yuichi Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan aut NATIONALLICENCE 700 1- Yonese Junji Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, 135-8550, Tokyo, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/6(2015-12-01), 1198-1202 1341-9625 20:6<1198 2015 20 10147